ライフサイエンスコーパス: maternal antibody

1 -9 months of life because of the presence of maternal antibody.

2 be vaccinated against MV in the presence of maternal antibody.

3 irth could prime immunity in the presence of maternal antibody.

4 ular responses in the presence or absence of maternal antibody.

5 d efficient transport of functionally active maternal antibody.

6 they are protected from disease, possibly by maternal antibody.

7 ssess high levels of potentially interfering maternal antibody.

8 h maternal antibody than among those without maternal antibody.

9 sence and absence of potentially interfering maternal antibodies.

10 d immunity in the presence of high levels of maternal antibodies.

11 ng infants is low because of interference by maternal antibodies.

12 exes, to overcome the suppressive effects of maternal antibodies.

13 ccur neonatally due to placental transfer of maternal antibodies.

14 birth, due to transplacental transmission of maternal antibodies.

15 er age 24 months, possibly indicating waning maternal antibodies.

16 tudy in human cohorts due to the presence of maternal antibodies.

17 feto-maternal tolerance, and the transfer of maternal antibodies.

18 veral variables influence the decay speed of maternal antibodies.

19 ng vaccine efficacy in neonatal animals with maternal antibodies.

20 er age 24 months, possibly indicating waning maternal antibodies.

21 tion in kits on the presence of pre-existing maternal antibodies.

22 turity and immunosuppression by RSV-specific maternal antibodies.

23 ection often relies on passively transmitted maternal antibodies.

24 t structural heart abnormalities and without maternal antibodies.

25 unter RSV in the presence of virus-specific (maternal) antibodies.

26 Fortunately, maternal antibodies (Abs) serve as a means to protect hu

27 Fc receptors transport maternal antibodies across epithelial cell barriers to p

28 fashion and raises the question of how many maternal antibodies affect brain development or exhibit

29 ibition of vaccine-induced seroconversion by maternal antibodies after vaccination remains a problem,

30 Induction of maternal antibodies against a commensal Pantoea species

31 lthough thrombocytopenia, which is caused by maternal antibodies against beta3 integrin and occasiona

32 le prevalence of autism; and the presence of maternal antibodies against fetal brain tissue.

33 s against beta3 integrin and occasionally by maternal antibodies against other platelet antigens, suc

34 esults from the transplacentally transmitted maternal antibodies against Rh factor D and can cause pe

35 Maternal antibodies against the envelope glycoprotein of

36 peared and was attenuated by the presence of maternal antibodies against the virus.

37 306 (93%) of 330 infants had seroprotective maternal antibodies against type 2 poliovirus at birth,

38 To establish that maternal antibody alone and not maternally derived T cel

39 However, these maternal antibodies also suppress neonatal B-cell respon

40 is still immature; however, the presence of maternal antibody also interferes with active immunizati

41 The estimated duration of protection by maternal antibodies among infants in the general populat

42 g previous RSV infections in the presence of maternal antibodies and can help in RSV clinical trials

43 fant responses to vaccines can be impeded by maternal antibodies and immune system immaturity.

44 during infancy and throughout life, despite maternal antibodies and immunity from prior infection an

45 ated with reduced transplacental transfer of maternal antibodies and increased risk of severe infecti

46 , passive transfer of MV-specific IgG mimics maternal antibodies and inhibits vaccine-induced serocon

47 ssibly, rubella have lower concentrations of maternal antibodies and lose protection by maternal anti

48 ty of vaccines can be modified in infancy by maternal antibodies and other immunizations.

49 erated after immunization in the presence of maternal antibodies and that the provision of alpha inte

50 rns regarding potential interference between maternal antibodies and the immune response elicited by

51 s evidence, together with the rapid decay of maternal antibodies and the observed cross-reactivity am

52 ildren vaccinated with MV in the presence of maternal antibody and 32.3 per 1000 person-years without

53 However, persistence of maternal antibody and young age affect the quantity of v

54 accine effectiveness, infant protection from maternal antibodies, and loss of immunity following chil

55 The role of breast milk, maternal diet, maternal antibodies, and microbiota that have been sugge

56 urally exposed to maternal allogeneic cells, maternal antibodies, and pathogens.

57 ype may be a pathologic process initiated by maternal antibodies, and persistence of this phenotype e

58 metric mean titres (GMTs), transfer ratio of maternal antibodies, and the dynamics of maternally and

59 against postnatal CMV infection afforded by maternal antibodies, and they support the continued incl

60 Maternal antibodies are known to suppress the B-cell res

61 IV3 disease must occur in early infancy when maternal antibodies are present, the live attenuated cp4

62 ation only fails to induce seroconversion if maternal antibodies are present.

63 ets and infants are anatomically similar and maternal antibodies are transferred and secreted by a si

64 varied widely; consistent with reports that maternal antibodies are transferred late in the third tr

65 Maternal antibodies are transferred transplacentally to

66 Maternal antibodies are transferred via the placenta and

67 f maternal antibodies and lose protection by maternal antibodies at an earlier age than children of m

68 GMCs of maternal antibodies at delivery (ELISA units/mL) were 2.

69 l report demonstrating a correlation between maternal antibody binding to epitopes within the carboxy

70 trum rich in IgG or IgA, and rodents acquire maternal antibodies both prenatally and postnatally.

71 on of HIV-1 offers a unique setting in which maternal antibodies both within the mother and passively

72 primary immune responses in the presence of maternal antibodies but was associated with a lower boos

73 an help to assess the hemolytic potential of maternal antibody, but quantitative measurement of subcl

74 HIV-1 envelope distinct from transplacental maternal antibody by age 12 weeks.

75 While we know that maternal antibodies can impair vaccine-induced immunity,

76 Although maternal antibodies can protect against infectious disea

77 Maternal antibodies can provide immunity, with maternal

78 These results suggest that maternal antibodies capable of activating AT1 receptors

79 fspring immune crosstalk include transfer of maternal antibodies, changes in the maternal microbiome

80 Maternal antibody concentration appeared more important

81 Maternal antibody concentrations and infant age at first

82 The association between GBS maternal antibody concentrations and the risk of neonata

83 lood antibody concentrations correlated with maternal antibody concentrations and with duration betwe

84 d on the underlying principle that increased maternal antibody concentrations are associated with an

85 ncy Tdap vaccination significantly increases maternal antibody concentrations in consecutive infants.

86 activated polio vaccine, where 2-fold higher maternal antibody concentrations resulted in 20% to 28%

87 Increased maternal antibody concentrations were associated with re

88 antigens, after adjusting for the effect of maternal antibody concentrations.

89 Although high concentrations of maternal antibodies correlate with poor production of an

90 ardless of the A(H1N1)pdm09-specific strain, maternal antibodies could be transferred efficiently via

91 Maternal antibodies cross the placenta and can afford so

92 e in reciprocal antibody titres adjusted for maternal antibody decay and was assessed in the modified

93 On the basis of the assumption that hPIV3 maternal antibody decays exponentially and constantly, t

94 s were further estimated after adjusting for maternal antibody decline.

95 For the two circulating pathogens, maternal antibodies declined exponentially after hatchin

96 rd trimester vaccination results in enhanced maternal antibody-dependent NK-cell activation, cellular

97 The low prevalence of maternal antibodies detected in Mexican children against

98 Maternal antibodies did not significantly reduce the eff

99 Thus, maternal antibody did not affect cell-mediated responses

100 In contrast, the presence of maternal antibody did not affect the generation of long-

101 The Fc-profile of neonatal and maternal antibodies differed, skewed toward natural kill

102 Maternal antibodies directed to pre-F, followed by antib

103 re the same immunity through the transfer of maternal antibodies during lactation.

104 Animal models are indispensable for studying maternal antibody effects on neonatal immunity because t

105 -lives of vaccine-induced pertussis-specific maternal antibodies, especially in preterm infants, and

106 fection in infants due to the persistence of maternal antibodies for a year or more.

107 ns as an accessible, retrospective source of maternal antibodies for estimating statewide seroprevale

108 ss postnatally, despite the clearance of the maternal antibodies from the neonatal circulation.

109 Moreover, passive transfer of maternal antibodies from vaccinated dams protected pups

110 Maternal antibodies fundamentally regulate gut immunity

111 maximal at the time of cardiac ontogeny when maternal antibodies gain access to the fetal circulation

112 rences between mother and father can lead to maternal antibody generation and hemolytic disease in ut

113 After the maternal antibodies had vanished, seroconversion to HPV-

114 Maternal antibody half-life was calculated using infant

115 e protection from infection, but gestational maternal antibodies have not yet been characterized in d

116 Maternal antibodies in breast milk play a key role in th

117 the first year of life and concentration of maternal antibodies in breastfeeding.

118 ates of the half-lives of pertussis-specific maternal antibodies in infants and explored potential ef

119 Because of this, protection by maternal antibodies in infants born to vaccinated mother

120 Studies of maternal antibodies in infants offer the potential to id

121 t of the data highlighted evidence of waning maternal antibodies in neonates, increasing seroprevalen

122 We demonstrate the presence of maternal antibodies in this system and accurately determ

123 binding resulted in enhanced accumulation of maternal antibody in the fetus.

124 the biologic half-life of human PIV3 (hPIV3) maternal antibody in young infants.

125 ajor players in the ionic mechanism by which maternal antibodies induce sinus bradycardia in CHB.

126 intended for populations with high titers of maternal antibodies (infants in developing countries) ma

127 These data demonstrate that maternal antibodies inhibit B-cell responses by interact

128 Preexisting maternal antibody inhibited infant antibody responses to

129 PUS: oocytes, providing strong evidence that maternal antibodies interact directly with the pore-form

130 , demonstrate in a neonatal mouse model that maternal antibodies interfere with oral rotavirus vaccin

131 Maternal antibody interference of the infant's humoral i

132 The inhibition of vaccination by maternal antibodies is a widely observed phenomenon in h

133 Maternal antibody is associated with a reduced infant re

134 Maternal antibody is the major form of protection from d

135 mechanism(s) responsible for acquisition of maternal antibody isotypes other than IgG are not fully

136 hanism(s) responsible for the acquisition of maternal antibody isotypes other than IgG are not fully

137 ssing the mechanism underlying inhibition by maternal antibodies, it has been suggested that epitope

138 However, if maternal antibodies lead to blunting, incidence increase

139 me coronavirus 2 (SARS-CoV-2) vaccination on maternal antibody levels and transplacental antibody tra

140 er among infants in the EPI arm who had high maternal antibody levels for all 3 poliovirus types (P<.

141 shedding is not inhibited despite comparable maternal antibody levels to the other cohorts.

142 Maternal antibodies lowered the final antibody responses

143 We here examine maternal antibody (MA) levels and their association with

144 VRP-based vaccines in other instances where maternal antibodies make early vaccination problematic.

145 vaccine design, understanding the nature of maternal antibodies may provide insights into immune mec

146 val when administered in early infancy, when maternal antibody may still be present.

147 le neonatal vaccination has been hampered by maternal antibody-mediated dampening of immune responses

148 Our findings show that maternal antibody-mediated vaccine clearance is a key me

149 ibody and 32.3 per 1000 person-years without maternal antibody (mortality rate ratio [MRR], 0.0; 95%

150 [PID] 21) with virulent HRV, the effects of maternal antibodies on protection (from diarrhea and vir

151 e candidates in infants and of the effect of maternal antibodies on vaccine efficacy will aid in the

152 at 16 and 18 weeks of age, and the effect of maternal antibody on Salmonella colonization of progeny

153 m by which FcRn may facilitate absorption of maternal antibodies other than IgG.

154 lues were lower for 6-month-old infants with maternal antibody (P=.0001), 6-month-old infants without

155 ibody (P=.0001), 6-month-old infants without maternal antibody (P=.001), 9-month-old infants with mat

156 ody (P=.03), and 9-month-old infants without maternal antibody (P=.006).

157 antibody (P=.001), 9-month-old infants with maternal antibody (P=.03), and 9-month-old infants witho

158 e aqueous microcapsules, was found to bypass maternal antibody passively transferred by suckling to n

159 d reovirus could bypass the normal effect of maternal antibodies, passively acquired by suckling, to

160 arting vaccination at age 6 months and among maternal antibody-positive participants who started vacc

161 Maternal antibodies prevented colonization of the chicks

162 stered to infant macaques in the presence of maternal antibody primes MV-specific T cell responses bu

163 Perturbed HIV-associated maternal antibody profiles are a key determinant of com-

164 Maternal antibody profiles were strikingly different bet

165 Passively acquired maternal antibodies protect infants from many pathogens.

166 Although maternal antibodies protect newborn babies from infectio

167 Further understanding of the bridge that maternal antibodies provide between the child and its en

168 There is evidence that maternal antibodies provide some protection from infecti

169 inue to circulate in pigs after the decay of maternal antibodies, providing a continuing source of vi

170 obulinemia was associated with lower cord-to-maternal antibody ratio.

171 Maternal antibody reduced the efficacy of vaccination of

172 The specificity of the newly acquired maternal antibodies reflected the amino acid sequence of

173 This study estimates the level of maternal antibody required to protect neonates against e

174 by and electron microscopy and measured the maternal antibody response in the blood to this infectio

175 No specific maternal antibody response was detected, eliminating the

176 Understanding maternal antibody response, duration, and transplacental

177 Maternal antibody responses in early pregnancy (mean ges

178 GBS6 induced maternal antibody responses to all serotypes, with mater

179 Understanding the dynamics of maternal antibody responses to severe acute respiratory

180 Immunization in the presence of maternal antibodies resulted in the development of a CD4

181 FNAIT arises when maternal antibodies specific for platelet antigens, most

182 imitations of the study included the lack of maternal antibody status (breast milk or plasma) or prev

183 e Coronavirus 2 (SARS-CoV-2) consistent with maternal antibody status, indicating transplacental tran

184 hallenging pups that were fostered by either maternal antibody-sufficient or antibody-deficient dams,

185 In utero exposure to maternal antibodies targeting the fetal acetylcholine re

186 Instead, we found higher maternal antibody targeting epitopes on CMV pentamer in

187 edian IgG level was lower among infants with maternal antibody than among those without maternal anti

188 This activity was linked to maternal antibodies that could bind bacteria in the neon

189 e rates that accounts for passively acquired maternal antibodies that decay or active immunity that w

190 hort-lived, and Th-2 biased responses and by maternal antibodies that interfere with vaccine take.

191 he first time, a parasite-specific target of maternal antibodies that protect infants from SM and sug

192 Ferrets without maternal antibody that were vaccinated intranasally (i.n

193 Ferrets with maternal antibody that were vaccinated parenterally with

194 Ferrets without maternal antibody that were vaccinated parenterally with

195 ge had lower mortality than children with no maternal antibody, the MRR being 0.22 (95% CI, .07-.64)

196 s currently being developed aim at inducing (maternal) antibodies, these results highlight the import

197 bodies in children increased with increasing maternal antibody titer (lytic, chi 21=26, and P<.001; l

198 ter dose between 6 and 8 months of age, when maternal antibody titer is low and severe rotavirus gast

199 tudy aimed to assess the correlation between maternal antibody titers against the pre-F, post-F, and

200 pups, although pup IgG levels increase when maternal antibody titers are very low.

201 ental ZIKV shedding and potential utility of maternal antibody titers to corroborate congenital ZIKV

202 tion assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1x10(5) TCID(5

203 not prevent the recurrence of CHB or reduce maternal antibody titers.

204 equal to four-fold higher than the estimated maternal antibody titre and more than or equal to 8 afte

205 Our results show that maternal antibody titres declined rapidly in neonates, w

206 Maternal antibodies to all tested HPV-6 proteins were tr

207 We measured the ability of maternal antibodies to block 3 key pentameric epitopes:

208 of age is unknown and passively transferred maternal antibodies to hepatitis A virus (maternal anti-

209 indicated a significant association between maternal antibodies to herpes simplex virus type 2 glyco

210 Transplacental transfer of NTS LPS-specific maternal antibodies to infants was highly efficient.

211 Maternal antibodies to pertussis can hamper infant immun

212 The immunized dams transfer maternal antibodies to pups, which protect neonates agai

213 Thus, the ability of maternal antibodies to suppress MK growth is a potential

214 Although the transplacental transfer of maternal antibodies to the fetus may convey improved pos

215 Because transplacentally acquired maternal antibodies to the GBS capsular polysaccharides

216 The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the

217 control persistent infections, and, through maternal antibody, to protect the host's immunologically

218 t epitope masking explains the inhibition by maternal antibodies, too.

219 orary direct protection of the infant due to maternal antibody transfer has efficacy for infants comp

220 rm infants to increase the time interval for maternal antibody transfer.

221 sulting in lower levels of serotype-specific maternal antibody transferred to infants, which could re

222 Maternal antibodies transported across the placenta can

223 son of vaccine administration (type 3 only), maternal antibody (type 3 only), and immunization campai

224 majority of infants will not be protected by maternal antibodies until their first measles vaccinatio

225 i.n.-parenteral immunization of ferrets with maternal antibody using NYVAC-HF (n = 9) produced higher

226 ccinating against measles in the presence of maternal antibody, using a 2-dose schedule with the firs

227 n to block vaccine replication, while faster maternal antibody waning is observed in vaccinated compa

228 After maternal antibody waning, there were periodic increases

229 More rapid decay of maternal antibodies was a major predictor of EBV infecti

230 acellular pertussis antigens, 2-fold higher maternal antibody was associated with 11% lower postvacc

231 Maternal antibody was detected in the progeny of vaccina

232 The influence of maternal antibody was still evident in reduced responses

233 To model vaccination in the presence of maternal antibodies, weanling pups born to DENV2-immune

234 Maternal antibodies were affected by placental infection

235 Maternal antibodies were detectable for the first 3 mont

236 Maternal antibodies were efficiently transferred to infa

237 ewborn monocytes and the reduced transfer of maternal antibodies were most intense following ART init

238 e a mature immune response and who may carry maternal antibodies which inactivate standard vaccines.

239 low passive, protective immunity via suckled maternal antibodies while permitting active oral immuniz

240 TRT and 3 with fetal thyroid suppression by maternal antibodies whose TRT was discontinued at a late

241 The effects of circulating maternal antibodies, with and without colostrum and milk